New immune therapy combo aims to keep myeloma in check
NCT ID NCT06353022
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether using teclistamab or talquetamab (immune cell redirectors) after initial treatment can improve outcomes for newly diagnosed multiple myeloma. 103 patients receive either teclistamab with lenalidomide or teclistamab with talquetamab, depending on their minimal residual disease (MRD) status. The goal is to achieve and maintain MRD negativity, which indicates very low levels of cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teclistamab and talquetamab (immune cell redirectors) with lenalidomide
What this could lead to
If successful, this could lead to a more personalized maintenance strategy that improves long-term control of multiple myeloma and reduces the chance of relapse.
What could go wrong
This is a phase 2 trial with only 103 participants, so results may not apply to all patients. The treatments can cause serious side effects like infections and immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP Hôpital La Pitié Salpétrière
Paris, 75013, France
-
APHP Hôpital Saint-Antoine
Paris, 75012, France
-
CH Lyon Sud
Lyon, 69495, France
-
CH de la Côte Basque
Bayonne, 64109, France
-
CHRU DIjon
Dijon, 21000, France
-
CHRU LILLE - Hôpital Claude Huriez
Lille, 59037, France
-
CHRU Nancy - Hôpitaux de Brabois
Vandœuvre-lès-Nancy, 54511, France
-
CHRU Rennes - Hôpital de Pontchaillou
Rennes, 35033, France
-
CHU BORDEAUX - Hôpital du Haut Lévêque
Pessac, 33604, France
-
CHU Caen
Caen, 14033, France
-
CHU Limoges
Limoges, 87000, France
-
CHU Montpellier
Montpellier, 34295, France
-
CHU Poitiers
Poitiers, 86000, France
-
CHU Toulouse
Toulouse, 31059, France
-
CHU Tours Hôpital Bretonneau
Tours, 37044, France
-
CHU de Nantes
Nantes, 44093, France
-
CHU de Strasbourg (HUS)
Strasbourg, 67200, France
-
Chd Vendee
La Roche-sur-Yon, 85925, France
-
IPC Marseille Institut Paoli Calmettes
Marseille, 13009, France